A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs

Molecular Pharmaceutics

Volumn 8, Issue 4, 2011, Pages 1257-1265

  Shin, Ho Chul ^a   Alani, Adam W G ^b   Cho, Hyunah ^a   Bae, Younsoo ^c   Kolesar, Jill M ^a   Kwon, Glen S ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; MACROGOL; PACLITAXEL; POLYLACTIC ACID; RAPAMYCIN; TANESPIMYCIN;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MICELLE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

BENZOQUINONES; CELL LINE, TUMOR; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LACTIC ACID; MICELLES; MODELS, THEORETICAL; PACLITAXEL; POLYETHYLENE GLYCOLS; POLYMERS; SIROLIMUS; SOLUBILITY; TOR SERINE-THREONINE KINASES; WATER;

EID: 79961076052     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp2000549     Document Type: Article

References (33)

1. Bagnyukova, T.; Serebriiskii, I. G.; Zhou, Y.; Hopper-Borge, E. A.; Golemis, E. A.; Astsaturov, I. Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents? Cancer Biol. Ther. 2010, 10 (9) 839-53
2. LoPiccolo, J.; Blumenthal, G. M.; Bernstein, W. B.; Dennis, P. A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations Drug Resist. Updates 2008, 11 (1-2) 32-50
3. Solit, D. B.; Basso, A. D.; Olshen, A. B.; Scher, H. I.; Rosen, N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol Cancer Res. 2003, 63 (9) 2139-44 (Pubitemid 36538618)
4. Munster, P. N.; Basso, A.; Solit, D.; Norton, L.; Rosen, N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin Cancer Res. 2001, 7, 2155-8
5. Clin. Cancer Res. 2001, 7, 8 2228-36.
6. Nguyen, D. M.; Lorang, D.; Chen, G. A.; Stewart, J. H. t.; Tabibi, E.; Schrump, D. S. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann. Thorac. Surg. 2001, 72, (2), 371-8; discussion 378-9.
7. Sain, N.; Krishnan, B.; Ormerod, M. G.; De Rienzo, A.; Liu, W. M.; Kaye, S. B.; Workman, P.; Jackman, A. L. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol. Cancer Ther. 2006, 5 (5) 1197-208 (Pubitemid 43881312)
8. Solit, D. B.; Chiosis, G. Development and application of Hsp90 inhibitors Drug Discovery Today 2008, 13 (1-2) 38-43
9. Mondesire, W. H.; Jian, W.; Zhang, H.; Ensor, J.; Hung, M. C.; Mills, G. B.; Meric-Bernstam, F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells Clin. Cancer Res. 2004, 10 (20) 7031-42 (Pubitemid 39383055)
10. Dancey, J. E. Therapeutic targets: MTOR and related pathways Cancer Biol. Ther. 2006, 5 (9) 1065-73 (Pubitemid 44773684)
11. Roforth, M. M.; Tan, C. Combination of rapamycin and 17-allylamino-17- demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells Anticancer Drugs 2008, 19 (7) 681-8
12. Bagatell, R.; Gore, L.; Egorin, M. J.; Ho, R.; Heller, G.; Boucher, N.; Zuhowski, E. G.; Whitlock, J. A.; Hunger, S. P.; Narendran, A.; Katzenstein, H. M.; Arceci, R. J.; Boklan, J.; Herzog, C. E.; Whitesell, L.; Ivy, S. P.; Trippett, T. M. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study Clin. Cancer Res. 2007, 13 (6) 1783-8 (Pubitemid 46952946)
13. Wang, X.; Sun, S. Y. Enhancing mTOR-targeted cancer therapy Expert Opin. Ther. Targets 2009, 13 (10) 1193-203
14. Aliabadi, H. M.; Lavasanifar, A. Polymeric micelles for drug delivery Expert Opin. Drug Delivery 2006, 3 (1) 139-62 (Pubitemid 43056397)
15. Kwon, G. S. Editorial for theme section on polymeric micelles for drug delivery Pharm. Res. 2008, 25 (9) 2053-5
16. Kim, D. W.; Kim, S. Y.; Kim, H. K.; Kim, S. W.; Shin, S. W.; Kim, J. S.; Park, K.; Lee, M. Y.; Heo, D. S. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer Ann. Oncol. 2007, 18 (12) 2009-14 (Pubitemid 350286241)
17. Lee, K. S.; Chung, H. C.; Im, S. A.; Park, Y. H.; Kim, C. S.; Kim, S. B.; Rha, S. Y.; Lee, M. Y.; Ro, J. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer Breast Cancer Res. Treat. 2008, 108 (2) 241-50 (Pubitemid 351311357)
18. Shin, H. C.; Alani, A. W.; Rao, D. A.; Rockich, N. C.; Kwon, G. S. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs J. Controlled Release 2009, 140 (3) 294-300
19. Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol. Rev. 2006, 58 (3) 621-81
20. Freireich, E. J.; Gehan, E. A.; Rall, D. P.; Schmidt, L. H.; Skipper, H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man Cancer Chemother. Rep. 1966, 50 (4) 219-44
21. Liggins, R. T.; Hunter, W. L.; Burt, H. M. Solid-state characterization of paclitaxel J. Pharm. Sci. 1997, 86 (12) 1458-63 (Pubitemid 28018330)
22. Simamora, P.; Alvarez, J. M.; Yalkowsky, S. H. Solubilization of rapamycin Int. J. Pharm. 2001, 213 (1-2) 25-9 (Pubitemid 32119459)
23. Sydor, J. R.; Normant, E.; Pien, C. S.; Porter, J. R.; Ge, J.; Grenier, L.; Pak, R. H.; Ali, J. A.; Dembski, M. S.; Hudak, J.; Patterson, J.; Penders, C.; Pink, M.; Read, M. A.; Sang, J.; Woodward, C.; Zhang, Y.; Grayzel, D. S.; Wright, J.; Barrett, J. A.; Palombella, V. J.; Adams, J.; Tong, J. K. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90 Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (46) 17408-13 (Pubitemid 44788982)
24. Merlin, J. L.; Barberi-Heyob, M.; Bachmann, N. In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines Ann. Oncol. 2002, 13 (11) 1743-8 (Pubitemid 35439454)
25. Xiong, M. P.; Yanez, J. A.; Kwon, G. S.; Davies, N. M.; Forrest, M. L. A cremophor-free formulation for tanespimycin (17-AAG) using PEO-b-PDLLA micelles: characterization and pharmacokinetics in rats J. Pharm. Sci. 2009, 98 (4) 1577-86
26. Robinson, B. W.; Ostruszka, L.; Im, M. M.; Shewach, D. S. Promising combination therapies with gemcitabine Semin. Oncol. 2004, 31 (2 Suppl. 5) 2-12 (Pubitemid 38658228)
27. ten Tije, A. J.; Verweij, J.; Loos, W. J.; Sparreboom, A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy Clin. Pharmacokinet. 2003, 42 (7) 665-85 (Pubitemid 36936530)
28. Banerji, U.; Walton, M.; Raynaud, F.; Grimshaw, R.; Kelland, L.; Valenti, M.; Judson, I.; Workman, P. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models Clin. Cancer Res. 2005, 11 (19 Part 1) 7023-32 (Pubitemid 41428762)
29. Kim, S. C.; Kim, D. W.; Shim, Y. H.; Bang, J. S.; Oh, H. S.; Wan Kim, S.; Seo, M. H. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy J. Controlled Release 2001, 72 (1-3) 191-202 (Pubitemid 32522357)
30. Hennenfent, K. L.; Govindan, R. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann. Oncol. 2006, 17 (5) 735-49
31. Marupudi, N. I.; Han, J. E.; Li, K. W.; Renard, V. M.; Tyler, B. M.; Brem, H. Paclitaxel: a review of adverse toxicities and novel delivery strategies Expert Opin. Drug Saf. 2007, 6 (5) 609-21 (Pubitemid 351308218)
32. Raymond, E.; Alexandre, J.; Faivre, S.; Vera, K.; Materman, E.; Boni, J.; Leister, C.; Korth-Bradley, J.; Hanauske, A.; Armand, J. P. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer J. Clin. Oncol. 2004, 22 (12) 2336-47 (Pubitemid 41115390)
33. Solit, D. B.; Ivy, S. P.; Kopil, C.; Sikorski, R.; Morris, M. J.; Slovin, S. F.; Kelly, W. K.; DeLaCruz, A.; Curley, T.; Heller, G.; Larson, S.; Schwartz, L.; Egorin, M. J.; Rosen, N.; Scher, H. I. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer Clin. Cancer Res. 2007, 13 (6) 1775-82 (Pubitemid 46952945)